Spontaneous Intracranial Hypotension Treatment "SIHT" (SIHT)

April 20, 2022 updated by: Assistance Publique - Hôpitaux de Paris

Parallel Randomised Open Blind Evaluation Study of the Efficacy of 20° Trendelenburg Position During 24 Hours After Epidural Blood Patch in the Treatment of Spontaneous Intracranial Hypotension

Spontaneous intracranial hypotension (SIH) is an infrequent disease, related to a leak of cerebrospinal fluid. There are not controlled studies for this treatment.The main of this study is to demonstrate the superiority of the Trendelenburg position compared to supine position during 24 hours after an epidural blood patch for a spontaneous intracranial hypotension

Study Overview

Detailed Description

Various treatments have been used for patient with spontaneous intracranial hypotension, but there is not definite approach. Some patients, fortunately, improve spontaneously. Bed rest and increased fluid intake have been advocate. The effectiveness of the caffeine has been shown in some studies, but durable beneficial effect is doubtful. The efficacy of steroids has not been established. However, although there have been no controlled studies, autologous epidural blood patch (EBP) can be considered the treatment of choice for patients. The success rate of EBP for a post lumbar puncture headache is about 90%, but for SIH, is very less about 50% after the first one and 77% after the second. The amount of blood injected must be sufficient. On the other hand, the leak is usually located on dorsal, above the prolonged rest must be respected. One study, have demonstrated, without randomization, a success rate of 90% with a prolonged Trendelenburg after EBP. We decided to do this study, to confirm a superiority of a 24 hours prolonged Trendelenburg position.

It's a monocentric study of parallel randomized open blind groups. Patients will be recruited by investigators in our headache emergency room. If the diagnose of SIH is confirmed (orthostatic headache from more than 5 days and less than 28 days with a normal MRI or with sign of SIH) study will be proposed.

After a signed information, the patients will be randomized in 2 groups, the investigator is blind of the randomized arm of patient

  1. EBP with 24 hours bed rest
  2. EBP with 24 hours Trendelenburg position

V1: inclusion V2 : 24 hours before EBP (headache, associated symptoms, HIT6) V3 : randomization and EBP V4 : first evaluation 30 minutes after standing (headaches, associated symptoms) V5 : phone evaluation (safety) D7 V6 : Evaluation at D15 (headache, associated symptoms, safety) V7 : Evaluation at D30 (headache, associated symptoms, control cerebral MRI, HIT6, safety) V8 : last evaluation D60 (headache, associated symptoms,HIT6 safety)

Collection of 2nd EBP, 3rd EBP, 4th EBP throughout the study up to J 92 maximum

Study Type

Interventional

Enrollment (Actual)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75010
        • Lariboisiere Hospital - Centre Urgences Céphalées (CUC)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 18 years or more
  • No contraindication for BPE
  • Severe or moderate headache within 15 min standing, mild or no headache after 15 min bed rest
  • Headache from 5 to 28 days
  • Normal or evidence of low CSF on MRI
  • Signed informed consent

Exclusion Criteria:

  • Known dural leak in the previous 2 months the onset of headache
  • Abnormal MRI
  • First BPE for SIH
  • The patient has participated in another clinical trial than can interact with the evaluation
  • Contraindication of Trendelenburg position

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: A : 24 hours bed rest
24 hours bed rest
24 hours bed rest after EBP
Other Names:
  • Allitement flat position for 24 hours
Autologous Epidural Blood Patch
Other Names:
  • Epidural Blood Patch
Experimental: B : 24 hours Trendelenburg position
24 hours Trendelenburg position
Autologous Epidural Blood Patch
Other Names:
  • Epidural Blood Patch
Trendelenburg position
Other Names:
  • inclination of the body at 20 degrees

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Recovery at Day 1 without relapse at Day 15
Time Frame: Day 1
V4: first evaluation 30 minutes after standing (headaches, associated symptoms) V6 : Evaluation at D15 (headache, associated symptoms, safety)
Day 1
Recovery at Day 1 without relapse at Day 15
Time Frame: day 15
V4: first evaluation 30 minutes after standing (headaches, associated symptoms) V6 : Evaluation at D15 (headache, associated symptoms, safety)
day 15

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
2d EBP and other EBP
Time Frame: day 7, 15, 30 and 60
Number of patients requires a treatment with a second BP at any time of study (withdrawal study)
day 7, 15, 30 and 60
Associated symptoms
Time Frame: day 1, 15, 30 and 60
Disappearance of associated symptoms
day 1, 15, 30 and 60
Headache
Time Frame: day 1,15, 30 and 60
Pain scores, localisation and type of persistent headache at day 1,15, 30 and 60
day 1,15, 30 and 60
subdural hematoma surgery
Time Frame: day 7, 15, 30 and 60
Number of patients requires a surgery for life-threatening acute SDH
day 7, 15, 30 and 60
cerebral MRI
Time Frame: day 30
results of D30 control MRI, compared to baseline MRI
day 30
medullar MRI
Time Frame: day 60
results of baseline medullar MRI and the link between leak and patient recovery
day 60
Epidural Blood Patch
Time Frame: day 60
Volume of blood and localisation of injection / statistical data related with recovery
day 60

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Caroline ROOS, MD, Assistance Publique - Hôpitaux de Paris

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2014

Primary Completion (Actual)

October 1, 2020

Study Completion (Actual)

March 8, 2021

Study Registration Dates

First Submitted

September 26, 2014

First Submitted That Met QC Criteria

October 7, 2014

First Posted (Estimate)

October 10, 2014

Study Record Updates

Last Update Posted (Actual)

April 21, 2022

Last Update Submitted That Met QC Criteria

April 20, 2022

Last Verified

April 1, 2022

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Spontaneous Intracranial Hypotension

Clinical Trials on 24 hours bed rest

Subscribe